In our study, DNMT3A mutation is a predictor of poor survival in terms of OS and PFS only in patients with SIAD, but not in the entire cohort, contrary to what was reported in a dedicated study.14 These data suggest that the DNMTA3 status merits to be analyzed in larger cohorts of CMML patients with SIAD as it seems to impact their prognosis. This evidence concerns the gene DNMT3A and chronic myelomonocytic leukemia.